2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
about
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.Inherent and iatrogenic immune defects in hairy cell leukemia: revisited.Hairy cell leukemia presenting as multiple discrete hepatic lesions.
P2860
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
@ast
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
@en
type
label
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
@ast
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
@en
prefLabel
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
@ast
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
@en
P2860
P1433
P1476
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
@en
P2093
Adi Gidron
P2860
P304
P356
10.1080/10428190600822052
P577
2006-11-01T00:00:00Z